AbbVie and Its Commitment to AI
AbbVie, a global leader in biopharmaceuticals, employs around 55,000 individuals across more than 70 countries. In 2024, the company allocated over $10.8 billion to research and development. This investment supports various clinical programs in immunology, oncology, and neuroscience.
To enhance the drug discovery process, AbbVie is leveraging artificial intelligence. This technology aids in improving decision-making during the early stages of drug development. By integrating AI, AbbVie aims to streamline operations and drive innovation in the biopharmaceutical sector.
